Serum MCP-1 levels are increased in mild cognitive impairment and mild Alzheimer's disease.
about
Tau-tubulin kinaseA deficiency in CCR2+ monocytes: the hidden side of Alzheimer's diseaseCCL2 accelerates microglia-mediated Abeta oligomer formation and progression of neurocognitive dysfunctionA blood-based screening tool for Alzheimer's disease that spans serum and plasma: findings from TARC and ADNIInflammatory Biomarkers and Cognitive Decline: The Ginkgo Evaluation of Memory Study.Pyroglutamate amyloid β (Aβ) aggravates behavioral deficits in transgenic amyloid mouse model for Alzheimer disease.Tau deposition drives neuropathological, inflammatory and behavioral abnormalities independently of neuronal loss in a novel mouse modelCCL2 affects β-amyloidosis and progressive neurocognitive dysfunction in a mouse model of Alzheimer's disease.Evidence for an immune role on cognition in schizophrenia: a systematic reviewBlocking IL-1 signaling rescues cognition, attenuates tau pathology, and restores neuronal β-catenin pathway function in an Alzheimer's disease model.Identification of peripheral inflammatory markers between normal control and Alzheimer's disease.Abnormal peripheral chemokine profile in Huntington's diseaseTherapeutic versus neuroinflammatory effects of passive immunization is dependent on Aβ/amyloid burden in a transgenic mouse model of Alzheimer's diseaseBody fluid cytokine levels in mild cognitive impairment and Alzheimer's disease: a comparative overview.Genome-wide association study of CSF levels of 59 alzheimer's disease candidate proteins: significant associations with proteins involved in amyloid processing and inflammationLongitudinal inflammation, cognitive decline, and Alzheimer's disease: a mini-reviewAn update on cancer- and chemotherapy-related cognitive dysfunction: current status.Decreased C-reactive protein levels in Alzheimer diseaseDifferential expression of cytokines in breast cancer patients receiving different chemotherapies: implications for cognitive impairment research.Two Blood Monocytic Biomarkers (CCL15 and p21) Combined with the Mini-Mental State Examination Discriminate Alzheimer's Disease Patients from Healthy SubjectsIncreased production of inflammatory cytokines in mild cognitive impairment.Alzheimer's Disease: Fatty Acids We Eat may be Linked to a Specific Protection via Low-dose Aspirin.An anti-inflammatory role for C/EBPδ in human brain pericytes.Can Genetic Analysis of Putative Blood Alzheimer's Disease Biomarkers Lead to Identification of Susceptibility Loci?sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer's disease and associate with neuronal injury markers.Multiple cytokines are involved in the early events leading to the Alzheimer's disease pathologyPeripheral chemo-cytokine profiles in Alzheimer's and Parkinson's diseasesThe isoenzyme of glutaminyl cyclase is an important regulator of monocyte infiltration under inflammatory conditions.Some hormone, cytokine and chemokine levels that change across lifespan vary by cognitive status in male Fischer 344 ratsCerebrospinal Fluid Markers of Alzheimer's Disease Pathology and Microglial Activation are Associated with Altered White Matter Microstructure in Asymptomatic Adults at Risk for Alzheimer's Disease.Expression profiles of cytokines in the brains of Alzheimer's disease (AD) patients compared to the brains of non-demented patients with and without increasing AD pathology.Short-term modern life-like stress exacerbates Aβ-pathology and synapse loss in 3xTg-AD miceSlow CCL2-dependent translocation of biopersistent particles from muscle to brain.Systemic immune system alterations in early stages of Alzheimer's disease.Glia maturation factor induces interleukin-33 release from astrocytes: implications for neurodegenerative diseases.MicroRNA deregulation and chemotaxis and phagocytosis impairment in Alzheimer's disease.Diverse activation of microglia by chemokine (C-C motif) ligand 2 overexpression in brain.Mediterranean diet and mild cognitive impairment.Identifying biomarkers of dementia prevalent among amnestic mild cognitively impaired ethnic female patients.Selective elevation of circulating CCL2/MCP1 levels in patients with longstanding post-vaccinal macrophagic myofasciitis and ASIA.
P2860
Q26829288-D45665F9-4F73-483E-BD4A-A9D44001787FQ26997058-4447833E-B8C1-4D67-BC3A-DB94479D5DBFQ27346578-F98F4D69-E4DB-42E7-850B-110DB82602B6Q28741766-1F9BB4E2-4C41-4AF4-94D8-649570EA417BQ30276553-D41346BA-C5BF-4A03-9638-071F965AF198Q30512697-DDD8F603-3D02-4130-B90E-A0A2C66620B7Q30667424-84ED9132-D296-4904-A545-BFAAF7C450A9Q33572146-4751BC10-B019-4E3D-9849-D2359820D54DQ33621692-67AFC6DB-14CD-46BC-8D52-45D4567ACD5EQ33810933-FBB07EC9-5A24-4B5D-88B3-7A08ACD2FC6FQ33898749-35FF6154-B570-4AD4-9BB1-6D1D34D75771Q33985904-8D0355CE-CBB1-4805-A716-2E0DB3173BA6Q34203381-3B883C9A-4331-4273-BA21-22FDBA82DDBEQ34277859-CC2EF5E1-BFBF-4383-8B8A-D9D1BA039FE0Q34394932-A493E4E3-9BF2-4ED5-9733-8019ABBB32BCQ34475359-FB9C7A9D-F9F9-42D1-9314-DDD90CFC2AEDQ35059702-381CC329-60B8-4CBE-A393-0E0DC3652E1AQ35482118-48B8C625-22F5-4064-9D28-9621197134F9Q35556085-771C85C5-EC7E-4838-8274-291A4F339411Q35607653-2467549D-F0CB-4E89-BEAB-B069C2A9D2D6Q35792619-44FD6AA5-6966-4D54-9A81-98E12A047070Q35806684-A255CD31-DE3A-4D49-A10A-E704515A420CQ35844497-46109018-218C-438F-BA7E-1EC1708B56ECQ35857246-6AC30230-3FC5-43B3-82CF-2F5FFF597AF0Q35945633-2FB9B9A6-31CB-47AB-AF0E-B92AA4CC6165Q35954373-8B5D39B3-2E54-4D8C-992E-8024469CF626Q36023238-8820F85D-029D-4A8F-892C-762094AC49CDQ36038807-FED3756D-013B-4F1B-BA29-022605CEB88FQ36052866-B8547D78-AF7E-4AA3-B165-D139009A32E7Q36599172-D5AD258A-BE95-47D0-A209-45BA84232985Q36611451-AB63A83D-2683-4882-B032-907A636B1CB4Q36687751-B074D7E6-D418-459C-AC5B-5598F1EFFCD1Q36741197-E0BD0A8F-C136-4ECA-8471-CE0F89C2CB49Q36810980-CFF0860D-63FA-48D5-BFFD-7B6DC0B20497Q36863846-BE477AC4-0512-41C8-9BCE-FA1E5666D228Q36934159-12F3335F-7DC4-471A-A809-593982E79810Q37053459-4D3018E1-F2BF-468B-8610-D311FC0E4CE7Q37121952-E2AC8E09-73DC-4A47-A128-FEE18BD4B9D1Q37346081-22F3F538-EBF1-41FA-A634-08C819A66FB0Q37405265-A9E8FD08-68CC-49B8-931C-9452B108776B
P2860
Serum MCP-1 levels are increased in mild cognitive impairment and mild Alzheimer's disease.
description
2005 nî lūn-bûn
@nan
2005 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Serum MCP-1 levels are increas ...... and mild Alzheimer's disease.
@ast
Serum MCP-1 levels are increas ...... and mild Alzheimer's disease.
@en
type
label
Serum MCP-1 levels are increas ...... and mild Alzheimer's disease.
@ast
Serum MCP-1 levels are increas ...... and mild Alzheimer's disease.
@en
prefLabel
Serum MCP-1 levels are increas ...... and mild Alzheimer's disease.
@ast
Serum MCP-1 levels are increas ...... and mild Alzheimer's disease.
@en
P2093
P50
P1476
Serum MCP-1 levels are increas ...... and mild Alzheimer's disease.
@en
P2093
Barbara Corrà
Claudio Mariani
Diego Scalabrini
Eliana Venturelli
Francesca Clerici
Ilaria Guidi
P304
P356
10.1016/J.NEUROBIOLAGING.2005.10.007
P577
2005-11-22T00:00:00Z